Fulcrum Therapeutics Inc
FULC7.630USD
-0.020-0.26%
收盘 11/07, 16:00（美东）报价延迟15分钟
412.85M总市值
亏损市盈率 TTM
关于 Fulcrum Therapeutics Inc 公司
Fulcrum Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司专注于改善在医疗需求尚未得到满足的领域患有遗传性罕见病的患者的生活。该公司的临床候选产品 losmapimod 是为治疗面肩肱型肌营养不良症 (FSHD) 而开发的。其另一个临床候选产品是 FTX-6058，用于治疗某些血红蛋白病，包括镰状细胞病 (SCD)。除了产品候选开发外，该公司还开发了一种药物发现方法，用于系统地识别和验证可能调节基因表达以治疗已知的遗传性罕见病根源的细胞药物靶点。该公司开发了 pociredir，旨在提高胎儿血红蛋白 (HbF) 水平，用于治疗 SCD 患者。
Fulcrum Therapeutics Inc简介
公司代码FULC
公司名称Fulcrum Therapeutics Inc
上市日期Jul 18, 2019
CEOMr. Alex C. Sapir
员工数量45
证券类型Ordinary Share
年结日Jul 18
公司地址26 Landsdowne Street
城市CAMBRIDGE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02139
电话16176518851
网址https://www.fulcrumtx.com/
公司代码FULC
上市日期Jul 18, 2019
CEOMr. Alex C. Sapir
Fulcrum Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Alan Ezekowitz, M.D., Ph.D.
Dr. Alan Ezekowitz, M.D., Ph.D.
Independent Director
Independent Director
28.93K
--
Mr. Curtis Gale Oltmans, J.D.
Mr. Curtis Gale Oltmans, J.D.
Chief Legal Officer
Chief Legal Officer
13.27K
+36.66%
Mr. Colin Hill
Mr. Colin Hill
Independent Director
Independent Director
--
--
Mr. Alex C. Sapir
Mr. Alex C. Sapir
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Kate Haviland
Ms. Kate Haviland
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. James Arthur (Jim) Geraghty, J.D.
Mr. James Arthur (Jim) Geraghty, J.D.
Independent Director
Independent Director
--
--
Dr. Robert J. Gould, Ph.D.
Dr. Robert J. Gould, Ph.D.
Independent Director
Independent Director
--
--
Mr. Alan A. Musso, CPA
Mr. Alan A. Musso, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Sonja L. Banks
Ms. Sonja L. Banks
Independent Director
Independent Director
--
--
Ms. Rachel King
Ms. Rachel King
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Alan Ezekowitz, M.D., Ph.D.
Dr. Alan Ezekowitz, M.D., Ph.D.
Independent Director
Independent Director
28.93K
--
Mr. Curtis Gale Oltmans, J.D.
Mr. Curtis Gale Oltmans, J.D.
Chief Legal Officer
Chief Legal Officer
13.27K
+36.66%
Mr. Colin Hill
Mr. Colin Hill
Independent Director
Independent Director
--
--
Mr. Alex C. Sapir
Mr. Alex C. Sapir
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Kate Haviland
Ms. Kate Haviland
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. James Arthur (Jim) Geraghty, J.D.
Mr. James Arthur (Jim) Geraghty, J.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
18.90%
TCG Crossover Management, LLC
9.70%
Suvretta Capital Management, LLC
9.39%
Adage Capital Management, L.P.
8.48%
Nantahala Capital Management, LLC
7.92%
其他
45.60%
持股股东
持股股东
占比
RA Capital Management, LP
18.90%
TCG Crossover Management, LLC
9.70%
Suvretta Capital Management, LLC
9.39%
Adage Capital Management, L.P.
8.48%
Nantahala Capital Management, LLC
7.92%
其他
45.60%
股东类型
持股股东
占比
Hedge Fund
36.90%
Investment Advisor
28.37%
Venture Capital
19.28%
Investment Advisor/Hedge Fund
13.05%
Research Firm
2.91%
Individual Investor
1.55%
Family Office
0.53%
Bank and Trust
0.38%
Pension Fund
0.17%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
303
54.75M
101.16%
-23.35M
2025Q2
310
52.98M
97.95%
-27.26M
2025Q1
331
52.80M
97.81%
-30.83M
2024Q4
337
53.60M
99.20%
-30.15M
2024Q3
332
56.49M
90.93%
-11.78M
2024Q2
311
66.33M
106.97%
-3.71M
2024Q1
311
61.90M
100.17%
-9.69M
2023Q4
303
62.48M
101.12%
-7.74M
2023Q3
308
58.43M
94.63%
-12.63M
2023Q2
308
57.40M
93.06%
-16.00M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
10.23M
18.91%
--
--
Jun 30, 2025
TCG Crossover Management, LLC
5.25M
9.71%
--
--
Jun 30, 2025
Suvretta Capital Management, LLC
5.08M
9.4%
+15.51K
+0.31%
Jun 30, 2025
Adage Capital Management, L.P.
4.59M
8.48%
+1.59M
+52.97%
Jun 30, 2025
Nantahala Capital Management, LLC
4.29M
7.93%
-534.39K
-11.08%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.72M
6.88%
-214.21K
-5.45%
Jun 30, 2025
The Vanguard Group, Inc.
3.15M
5.82%
-73.94K
-2.30%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.37M
2.54%
-34.41K
-2.45%
Jun 30, 2025
Balyasny Asset Management LP
1.34M
2.47%
+1.34M
--
Jun 30, 2025
State Street Investment Management (US)
1.22M
2.25%
-34.07K
-2.72%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
iShares Neuroscience and Healthcare ETF
0.79%
Simplify Health Care ETF
0.61%
Vanguard US Momentum Factor ETF
0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.08%
iShares Micro-Cap ETF
0.08%
Avantis US Small Cap Equity ETF
0.07%
Principal U.S. Small-Cap ETF
0.06%
iShares Russell 2000 Value ETF
0.03%
Invesco Dynamic Buyback Achievers ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
查看更多
iShares Neuroscience and Healthcare ETF
占比0.79%
Simplify Health Care ETF
占比0.61%
Vanguard US Momentum Factor ETF
占比0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.08%
iShares Micro-Cap ETF
占比0.08%
Avantis US Small Cap Equity ETF
占比0.07%
Principal U.S. Small-Cap ETF
占比0.06%
iShares Russell 2000 Value ETF
占比0.03%
Invesco Dynamic Buyback Achievers ETF
占比0.02%
Invesco RAFI US 1500 Small-Mid ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
